View Single Post
Old 09-25-2013, 11:57 AM   #1
Senior Member
'lizbeth's Avatar
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Ganetespib For Metastatic HER2+ or Triple Negative Disease

Ganetespib For Metastatic HER2+ or Triple Negative Disease

An Open Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib(STA-9090) Monotherapy in Women With Previously Untreated Metastatic HER2 Positive or Triple Negative Breast Cancer (9090-11)

Ganetespib (STA-9090) is an investigational drug. It is an Hsp90 inhibitor: It works by blocking Hsp90 (heat shock protein 90), a molecular chaperone that plays a role in cell signaling. Hsp90 has been studied in previous trials that have enrolled patients with HER2-positive tumors. It may also be an effective way to treat triple negative (ER-,PR- and HER2-) breast cancer. The purpose of this study is to determine if ganetespib is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment for metastatic disease.hibition may be an important new approach to treating triple negative breast cancer.
This is a Phase II trial
'lizbeth is offline   Reply With Quote